Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy
Author(s): Laque Larissa C, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C
Issue: Jan/Feb 2019 - Volume 23, Number 1
View All Articles in Issue
Page(s): 77-81
Download in electronic PDF format for $75
Abstract: The purpose of this study was to evaluate the transmucosal permeation of progesterone and testosterone using Pentravan as its vehicle for vaginal delivery. Progesterone deficiency is a hormone imbalance that could lead to luteal-phase deficiency, which is a common problem in assisted reproductive technologies. Testosterone has been explored for treating postmenopausal symptoms, such as vaginal atrophy. The ex vivo experiments were performed using porcine vaginal mucosa and phosphate buffered saline + 0.5% 2-hydroxypropyl-ß-cyclodextrin as the receptor media, which was later quantified through high-performance liquid chromatography. The percentage of the permeated drug was 0.4% and 20.3% for progesterone and testosterone, respectively. The permeation studies revealed that testosterone formulated with Pentravan is potentially effective in reaching the bloodstream and acts locally, whereas progesterone was mostly retained in the mucosa.
Related Keywords:
progesterone, testosterone, intravaginal administration, vaginal preparation, transmucosal permeation, vaginal atrophy, formulation, luteal phase deficiency, menopausal women, liposomal vehicle
Related Categories:
FORMULATIONS, HRT, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy
Laque Larissa C, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C
|
Jan/Feb 2019
Pg. 77-81
|
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome
Riepl Mike
|
Nov/Dec 2018
Pg. 456-465
|
Gentian Violet Vaginal Suppositories
Allen Loyd V Jr
|
Nov/Dec 2009
Pg. 556
|
Estradiol 0.1% Vaginal Solution
Allen Loyd V Jr
|
Jan/Feb 2024
Pg. 58
|
Estradiol 0.1% Vaginal Solution
Allen Loyd V Jr
|
Sep/Oct 2008
Pg. 450
|
Mupirocin 1% (20-mg) Vaginal Suppository
Allen Loyd V Jr
|
Jul/Aug 2009
Pg. 338
|
Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study
Lima Ramona, Gonzalez Mark A, Urwin Craig, Jean Linda, Carvalho Maria, Banov Fabiana
|
Mar/Apr 2023
Pg. 108-112
|
Case Report of a Human Papillomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications
Agbi Kelechi E, Hover Sara, Carvalho Maria
|
May/Jun 2018
Pg. 196-202
|
Nystatin 100,000-units Vaginal Inserts
Allen Loyd V Jr
|
Jul/Aug 2016
Pg. 322
|
Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases
Allen Loyd V Jr
|
May/Jun 2017
Pg. 238
|
Clindamycin 100-mg Vaginal Suppositories
Allen Loyd V Jr
|
Jul/Aug 2009
Pg. 334
|
Progesterone Vaginal Suppositories (Fatty Acid Base)
Allen Loyd V Jr
|
Jan/Feb 2024
Pg. 63
|
Progesterone 3% Vaginal Gel
Allen Loyd V Jr
|
Jan/Feb 1998
Pg. 58
|
Progesterone Vaginal Cream (5%)
Allen Loyd V Jr
|
Jan/Feb 1998
Pg. 64
|
Progesterone Vaginal Suppositories (Fatty Acid Base)
Allen Loyd V Jr
|
Jan/Feb 1998
Pg. 65
|
Progesterone Vaginal Suppositories (Polyethylene Glycol Bases)
Allen Loyd V Jr
|
Jan/Feb 1998
Pg. 66
|
Testosterone 1-mg/0.1-mL Topical Vaginal/Scrotal Spray
Allen Loyd V Jr
|
Nov/Dec 2000
Pg. 464
|
Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application
Polonini Hudson, de Oliveira Ferreira Anderson, Dijkers Eli
|
Sep/Oct 2021
Pg. 422-426
|
Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Glaser Rebecca L, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
|
Jul/Aug 2009
Pg. 314-317
|
Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Needham Shawn, Needham Shane
|
Nov/Dec 2018
Pg. 466-468
|
Return to Top |